TN2009000390A1 - Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma - Google Patents

Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma

Info

Publication number: TN2009000390A1
Authority: TN; Tunisia
Prior art keywords: asthma; composition; formoterol; exacerbation; prevention
Prior art date: 2007-04-19

Application number

TNP2009000390A

Other languages

English (en)

Inventor

Paolo Chiesi

Ivano Rondelli

Daniela Acerbi

Gianluigi Poli

Original Assignee

Chiesi Farmaceuticat S P A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-19

Filing date

2009-09-24

Publication date

2010-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000390(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-24 Application filed by Chiesi Farmaceuticat S P A filed Critical Chiesi Farmaceuticat S P A

2010-12-31 Publication of TN2009000390A1 publication Critical patent/TN2009000390A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

TNP2009000390A 2007-04-19 2009-09-24 Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma TN2009000390A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07007930A EP1982709A1 (fr)	2007-04-19	2007-04-19	Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
PCT/EP2008/003012 WO2008128685A1 (fr)	2007-04-19	2008-04-16	Utilisation d'une composition comprenant du formotérol et du dipropionate de béclométasone pour la prévention et/ou le traitement d'une crise d'asthme

Publications (1)

Publication Number	Publication Date
TN2009000390A1 true TN2009000390A1 (en)	2010-12-31

Family

ID=38458097

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000390A TN2009000390A1 (en)	2007-04-19	2009-09-24	Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma

Country Status (29)

Country	Link
US (1)	US20080261932A1 (fr)
EP (3)	EP1982709A1 (fr)
JP (2)	JP5492072B2 (fr)
KR (3)	KR101621676B1 (fr)
CN (1)	CN101657191B (fr)
AU (1)	AU2008241045C1 (fr)
BR (1)	BRPI0809800A2 (fr)
CA (1)	CA2684539A1 (fr)
CO (1)	CO6220945A2 (fr)
CY (1)	CY1117568T1 (fr)
DK (1)	DK2146704T3 (fr)
EA (1)	EA018589B1 (fr)
ES (2)	ES2568497T3 (fr)
GE (1)	GEP20145999B (fr)
HR (1)	HRP20160588T1 (fr)
HU (1)	HUE029263T2 (fr)
IL (1)	IL201632A (fr)
MA (1)	MA31315B1 (fr)
ME (1)	ME00945B (fr)
MX (1)	MX2009010851A (fr)
MY (1)	MY169579A (fr)
NZ (1)	NZ580526A (fr)
PL (2)	PL2146704T3 (fr)
RS (1)	RS54874B1 (fr)
SI (1)	SI2146704T1 (fr)
TN (1)	TN2009000390A1 (fr)
TR (1)	TR201909857T4 (fr)
UA (1)	UA100237C2 (fr)
WO (1)	WO2008128685A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1982709A1 (fr) *	2007-04-19	2008-10-22	CHIESI FARMACEUTICI S.p.A.	Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
WO2011038872A1 (fr) *	2009-10-02	2011-04-07	Chiesi Farmaceutici S.P.A.	Formulations d'aérosol pharmaceutique de formotérol et de dipropionate de béclométasone
CN102247597B (zh) *	2010-05-19	2015-01-07	天津金耀集团有限公司	一种糖皮质激素与支气管扩张剂的吸入剂
EP3527197B1 (fr) *	2012-01-25	2022-09-07	Chiesi Farmaceutici S.p.A.	Formulation de poudre sèche comprenant un corticostéroïde et un béta-adrénergique pour l'administration par inhalation
US11052202B2 (en) *	2012-11-07	2021-07-06	Chiesi Farmaceutici S.P.A.	Drug delivery device for the treatment of patients with respiratory diseases
UA124240C2 (uk) *	2016-09-19	2021-08-11	Мехікем Флуор С.А. Де С.В.	Фармацевтична композиція
CN107233311B (zh) *	2017-06-27	2020-12-04	长风药业股份有限公司	一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2019236559A1 (fr) *	2018-06-04	2019-12-12	Lupin Inc.	Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
CN120076800A (zh) *	2022-11-03	2025-05-30	丹娜法伯癌症研究院	使用福莫特罗或其药学上可接受的盐治疗贫血症的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5795564A (en) *	1991-04-05	1998-08-18	Sepracor, Inc.	Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SK285910B6 (sk)	1991-12-18	2007-10-04	Aktiebolaget Astra	Medicinálny produkt obsahujúci kombináciu formoterolu a budesonidu
SE9802073D0 (sv)	1998-06-11	1998-06-11	Astra Ab	New use
DZ3358A1 (fr)	2000-05-22	2001-11-29	Chiesi Farma Spa	Formulations en solution pharmaceutiques pour inhalateurs-doseurs sous pression
FI20002177A0 (fi) *	2000-10-02	2000-10-02	Orion Yhtymae Oyj	Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi)	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) *	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit
KR100947409B1 (ko)	2002-03-01	2010-03-12	키에시 파르마슈티시 엣스. 피. 에이.	포모테롤 초미세 조성물
EP1982709A1 (fr)	2007-04-19	2008-10-22	CHIESI FARMACEUTICI S.p.A.	Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme

2007
- 2007-04-19 EP EP07007930A patent/EP1982709A1/fr not_active Withdrawn
2008
- 2008-04-16 ES ES08748930.8T patent/ES2568497T3/es active Active
- 2008-04-16 PL PL08748930.8T patent/PL2146704T3/pl unknown
- 2008-04-16 ME MEP-2009-315A patent/ME00945B/fr unknown
- 2008-04-16 HU HUE08748930A patent/HUE029263T2/en unknown
- 2008-04-16 UA UAA200909905A patent/UA100237C2/uk unknown
- 2008-04-16 KR KR1020157017841A patent/KR101621676B1/ko active Active
- 2008-04-16 TR TR2019/09857T patent/TR201909857T4/tr unknown
- 2008-04-16 NZ NZ580526A patent/NZ580526A/en unknown
- 2008-04-16 WO PCT/EP2008/003012 patent/WO2008128685A1/fr not_active Ceased
- 2008-04-16 AU AU2008241045A patent/AU2008241045C1/en active Active
- 2008-04-16 ES ES16152451T patent/ES2740103T3/es active Active
- 2008-04-16 MX MX2009010851A patent/MX2009010851A/es active IP Right Grant
- 2008-04-16 EP EP08748930.8A patent/EP2146704B1/fr active Active
- 2008-04-16 KR KR1020157005890A patent/KR101668203B1/ko active Active
- 2008-04-16 RS RS20160439A patent/RS54874B1/sr unknown
- 2008-04-16 SI SI200831597A patent/SI2146704T1/sl unknown
- 2008-04-16 CN CN200880012407.9A patent/CN101657191B/zh active Active
- 2008-04-16 PL PL16152451T patent/PL3034073T3/pl unknown
- 2008-04-16 CA CA002684539A patent/CA2684539A1/fr not_active Abandoned
- 2008-04-16 GE GEAP200811515A patent/GEP20145999B/en unknown
- 2008-04-16 MY MYPI20094314A patent/MY169579A/en unknown
- 2008-04-16 HR HRP20160588TT patent/HRP20160588T1/hr unknown
- 2008-04-16 EA EA200901201A patent/EA018589B1/ru not_active IP Right Cessation
- 2008-04-16 KR KR1020097019229A patent/KR20100014408A/ko not_active Abandoned
- 2008-04-16 DK DK08748930.8T patent/DK2146704T3/en active
- 2008-04-16 JP JP2010503394A patent/JP5492072B2/ja active Active
- 2008-04-16 EP EP16152451.7A patent/EP3034073B1/fr active Active
- 2008-04-16 BR BRPI0809800-0A2A patent/BRPI0809800A2/pt not_active Application Discontinuation
- 2008-04-21 US US12/106,493 patent/US20080261932A1/en not_active Abandoned
2009
- 2009-09-24 TN TNP2009000390A patent/TN2009000390A1/fr unknown
- 2009-10-13 CO CO09113200A patent/CO6220945A2/es not_active Application Discontinuation
- 2009-10-15 MA MA32284A patent/MA31315B1/fr unknown
- 2009-10-19 IL IL201632A patent/IL201632A/en active IP Right Grant
2013
- 2013-10-18 JP JP2013217531A patent/JP2014005312A/ja not_active Withdrawn
2016
- 2016-04-14 CY CY20161100313T patent/CY1117568T1/el unknown

Also Published As

Publication number	Publication date
UA100237C2 (uk)	2012-12-10
MY169579A (en)	2019-04-22
PL3034073T3 (pl)	2019-11-29
KR20100014408A (ko)	2010-02-10
CY1117568T1 (el)	2017-04-26
EP3034073A1 (fr)	2016-06-22
ES2568497T3 (es)	2016-04-29
MX2009010851A (es)	2009-11-05
IL201632A (en)	2016-09-29
EP3034073B1 (fr)	2019-06-12
MA31315B1 (fr)	2010-04-01
HRP20160588T1 (hr)	2016-07-01
GEP20145999B (en)	2014-01-10
KR20150082699A (ko)	2015-07-15
IL201632A0 (en)	2010-05-31
JP5492072B2 (ja)	2014-05-14
NZ580526A (en)	2012-07-27
CO6220945A2 (es)	2010-11-19
JP2014005312A (ja)	2014-01-16
KR101621676B1 (ko)	2016-05-16
EP2146704B1 (fr)	2016-03-23
CN101657191A (zh)	2010-02-24
ES2740103T3 (es)	2020-02-05
EA018589B1 (ru)	2013-09-30
BRPI0809800A2 (pt)	2014-10-07
CN101657191B (zh)	2014-06-11
EP2146704A1 (fr)	2010-01-27
WO2008128685A1 (fr)	2008-10-30
AU2008241045A1 (en)	2008-10-30
RS54874B1 (sr)	2016-10-31
HUE029263T2 (en)	2017-02-28
TR201909857T4 (tr)	2019-07-22
EP1982709A1 (fr)	2008-10-22
KR101668203B1 (ko)	2016-10-20
US20080261932A1 (en)	2008-10-23
DK2146704T3 (en)	2016-05-23
AU2008241045C1 (en)	2023-06-15
SI2146704T1 (sl)	2016-05-31
PL2146704T3 (pl)	2016-09-30
HK1137357A1 (en)	2010-07-30
EA200901201A1 (ru)	2010-04-30
AU2008241045B2 (en)	2013-06-20
ME00945B (fr)	2012-06-20
JP2010524873A (ja)	2010-07-22
CA2684539A1 (fr)	2008-10-30
KR20150038618A (ko)	2015-04-08

Publication	Publication Date	Title
TN2009000390A1 (en)	2010-12-31	Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma
EP2749280A3 (fr)	2014-08-20	Composition pharmaceutique de glycopyrronium et formotérol
EP2671584A3 (fr)	2014-03-26	Compositions et procédés pour traiter des troubles associés à la rétention de sel ou de fluide
CA2909335C (fr)	2021-05-18	Fenfluramine destinee a etre utilisee pour le traitement du syndrome de dravet
MX2007008379A (es)	2008-02-19	Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
TR201000680A2 (tr)	2011-08-22	Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
UA98839C2 (en)	2012-06-25	N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2011041632A3 (fr)	2011-08-18	Thérapies combinées pour le traitement de l'obésité
WO2010045417A3 (fr)	2010-07-29	Polytherapies pour le traitement de l'obesite
MX2010002735A (es)	2010-04-01	Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
WO2010151565A3 (fr)	2011-05-05	Multithérapies pour le traitement de l'obésité
WO2010151503A3 (fr)	2011-05-05	Multithérapies pour le traitement de l'obésité
TW200718689A (en)	2007-05-16	2-Amino-quinazolin-5-ones
PH12019500315A1 (en)	2020-01-20	Combination therapy for copd
WO2007062093A3 (fr)	2008-10-23	Polytherapie pour le traitement du cancer
JP2007119497A5 (fr)	2008-04-24
MX2009001433A (es)	2009-04-09	Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
WO2010045522A3 (fr)	2010-07-22	Thérapies de combinaison pour le traitement de l'obésité
WO2011009115A3 (fr)	2011-05-12	Thérapies combinées destinées à traiter l'obésité
WO2010048384A3 (fr)	2010-09-02	Compositions d'arformotérol et de tiotropium et leurs procédés d'utilisation
MX2010005009A (es)	2010-05-27	Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
MX2021001349A (es)	2021-04-13	Un nuevo tratamiento medico para la inflamacion patologica.
WO2011008490A3 (fr)	2011-05-12	Thérapies de combinaison pour le traitement de l'obésité
WO2007041388A3 (fr)	2007-11-08	Prevention et traitement de troubles auditifs
WO2005120518A3 (fr)	2006-05-26	Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires